Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-synuclein shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Alpha-synuclein shRNA is a gene-silencing therapeutic platform designed to downregulate the expression of alpha-synuclein (aSyn), a protein whose pathological aggregation into Lewy bodies is a hallmark of Parkinson's disease and other synucleinopathies. By utilizing short hairpin RNA (shRNA) delivered via viral vectors (such as adeno-associated virus or lentivirus) or non-viral vehicles (such as exosomes or nanoparticles), this approach targets the SNCA transcript to reduce endogenous monomeric alpha-synuclein levels. Lowering the pool of available alpha-synuclein monomers has been shown to mitigate pathological seeding, reduce aggregation, and protect against neurodegeneration in preclinical models of Parkinson's disease.
- Other names
- alpha-synuclein short hairpin RNAanti-alpha-synuclein shRNAanti-α-synuclein shRNAα-synuclein shRNA
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on alpha-synuclein shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-synuclein shRNA.